USPTO serial 79175768
D DOMPÉ
Reviewed by CopyMark Law Group
Reg. 5126200Status 404
- Filing date
- Status date
- Registration date
- Jan 24, 2017
- Examiner
- THOMAS, JULIE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with D DOMPÉ?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Elizabeth Brenckman
Elizabeth Brenckman Fish & Richardson P.C.P.O. Box 1022Minneapolis, MN 55440UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparation for the treatment of respiratory diseases; pharmaceutical preparation for the treatment of bone diseases; analgesic and muscle relaxant pharmaceutical preparations; antibacterial pharmaceuticals; anti-epileptic pharmaceutical preparations; balms for pharmaceutical purposes; capsules sold empty for pharmaceuticals; cardiovascular pharmaceuticals; gelatin capsules sold empty for pharmaceuticals; ocular pharmaceuticals; pharmaceutical products for ophthalmological use; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases also rare; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases; pharmaceutical antitussive cold pharmaceutical preparations for use in chemotherapy; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in tissue and organ transplantation also rare; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations, namely, anticoagulants; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for treating diabetes also rare; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, an analgesic for human consumption taken orally; sanitary preparations for medical purposes; all-purpose disinfectants | SECTION 71 - CANCELLED | — |
| 041 | Entertainment television news programme services in the field of pharmaceutical products and sanitary preparations for medical purposes broadcast over the internet; organizing community festivals featuring primarily pharmaceutical exhibition for medical purposes; arranging professional workshop and training courses in the field of pharmaceutical products and medicine for medical purposes; training services in the field of pharmaceutical and sanitary preparations for medical purposes; education service, namely, providing tutoring in the field of pharmaceutical and sanitary preparations for medical purposes; providing information relating to organizing community cultural activities and contests | SECTION 71 - CANCELLED | — |
| 042 | Conducting early evaluations in the field of new pharmaceuticals; conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmology, treatment of cancer, diabetes, analgesic preparations, nerve grow factors, oncology, organ transplantation, antibiotics, respiratory diseases, bone diseases, rare diseases; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, medical diagnostics, drug development and pharmacogenetics; development of pharmaceutical preparations and medicines; laboratory research services relating to pharmaceuticals; research and development of pharmaceuticals for the treatment of cancer, diabetes, respiratory diseases, bone diseases, rare diseases, ocular disorders and diseases; research and development in the pharmaceutical and biotechnology fields | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by DOMPE' FARMACEUTICI S.P.A.
- Other trademarks owned by DOMPE' FARMACEUTICI S.P.A.
- Other trademarks owned by DOMPE' FARMACEUTICI S.P.A.
- Other trademarks in Class 005
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named D DOMPÉ
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 18, 2025 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Jul 18, 2025 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| May 6, 2024 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Apr 13, 2024 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Apr 13, 2024 | INPC | INVALIDATION PROCESSED | — |
| Apr 4, 2024 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Aug 4, 2023 | C71T | CANCELLED SECTION 71 | — |
| Jan 24, 2022 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jun 4, 2021 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Feb 12, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 20, 2017 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 26, 2017 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 26, 2017 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 24, 2017 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 24, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 18, 2016 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 8, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 8, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 19, 2016 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 19, 2016 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 19, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 28, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 28, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 28, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 28, 2016 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jun 30, 2016 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 30, 2016 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 30, 2016 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 2, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 1, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 1, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 28, 2016 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 18, 2015 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 1, 2015 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 1, 2015 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 26, 2015 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 25, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 19, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 17, 2015 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 12, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 12, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 10, 2015 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Nov 7, 2015 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |